Follows liver fat and scarring in adults with type 2 diabetes over time
Checks how fatty liver disease changes over time in people with type 2 diabetes.
Key facts
- Who runs it
- Linkoeping University
- Where
- Linköping, SwedenSee the site
- Trial code
- Registry title
- MASLD in Type 2 Diabetes in Primary Care - a Follow-up Study
- Status
- Enrolling by invitation
- People taking part
- 317 people, planned
- Started
- 16 Dec 2025
- Expected to end
- 31 Dec 2034
- Type of study
- Observational
- Record updated
- 9 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with type 2 diabetes who took part in the EPSONIP study and finished its assessments. It follows how their liver disease (MASLD) changes over time.
- Age
- 18 years or older
- Sex
- All sexes can join
- Earlier treatment
- Must have been included in the EPSONIP study (NCT03864510) and completed its assessments.
Main reasons for not taking part
- Cannot have an MRI scan because of a contraindication
- Another main liver disease besides MASLD, found after joining the EPSONIP study
- Liver transplantation
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Previously included and completed the assessments in the EPSONIP study (NCT03864510)
- Age >/= 18 years
- Informed consent
Who cannot take part
- Liver transplantation
- Other primary liver disease than MASLD diagnosed after inclusion in the EPSONIP study (NCT03864510)
- Contraindication to magnetic resonance imaging
Where in Sweden
- Department of Gastroenterology and Hepatology, Linköping University HospitalLinköping, SwedenNo longer taking part
About the trial
What the trial wants to find out
The goal of this observational study is to understand how metabolic dysfunction-associated steatotic liver disease (MASLD) changes over time in individuals with type 2 diabetes who previously participated in the EPSONIP study.
Read full original descriptionShow less
The main questions it aims to answer are:
1. How common are MASLD and advanced liver fibrosis at long-term follow-up? 2. Which factors are associated with progression or regression of liver fat accumulation and liver fibrosis over time?
Participants will:
* Undergo a clinical examination and review of medical history. * Provide blood, urine, and biobank samples. * Undergo liver assessment using vibration-controlled transient elastography (VCTE). * Undergo magnetic resonance imaging (MRI) to assess liver fat, liver fibrosis, and body composition. * Complete questionnaires regarding lifestyle and physical activity. * Undergo physical activity measurements using accelerometers and additional assessments related to blood pressure and sleep apnea.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Evaluating the Prevalence and Severity of MASLD in Primary Care - a Follow-up Study
- Plain-language title
- Follows liver fat and scarring in adults with type 2 diabetes over timeGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 9 October 2026